Real-world persistence of twice-weekly teriparatide and factors associated with the discontinuation in patients with osteoporosis.

Ryo FujitaTsutomu EndoMasahiko TakahataKentaro HarayaHisataka SuzukiItaru OdaMasahiro KanayamaTsuyoshi AsanoKeiichi ShigenobuAkira IwataKatsuhisa YamadaHirohito TakeuchiHisanori OhuraDaisuke YoneokaNorimasa Iwasaki

Published in: Journal of bone and mineral metabolism (2022)

One year continuation rate of 2/W-TPD was higher than the previously reported value of the once-weekly formulation in real-world setting, probably due to the lower incidence of side effects. Introducing injection of 2/W-TPD may further improve the persistence of TPD therapy for osteoporosis.

Keyphrases

bone mineral density
postmenopausal women
body composition
risk factors
drug delivery